Myeloma Articles & Analysis: Older
43 news found
It provides customers with comprehensive solutions including instruments, consumables, reagents, and software for the analysis of gene loci related to birth defect prevention and control, drug genomes, tumours, infectious diseases, and other fields.GETOTEC, a fully-automated capillary electrophoresis instrument, ClinCap 1000, with independent intellectual property rights under FPI Life Sciences, ...
In 2009, as a graduate student at the University of Wisconsin-Madison, Chorom Pak was part of a group of researchers working to understand how sensitive patients’ cells were to certain therapies for blood cancers, such as multiple myeloma. The group, which also included UW-Madison professors Shigeki Miyamoto and David Beebe, and postdoctoral fellow Edmond ...
Lynx Biosciences founder and CEO Chorom Pak said her startup has developed microfluidic technology that uses live cancer cells to determine how multiple myeloma patients would respond to different treatment regimens. The Wednesday evening pitch event drew several hundred people to an auditorium at Qualcomm’s (NASDAQ: QCOM) corporate headquarters in San Diego. ...
“This minimally invasive approach to capturing myeloma cells in blood, is not only important to identify patients at higher risk of progression but could potentially reduce the need for bone marrow ...
Stemline also commercializes Nexpovio® in Europe, an XPO1 inhibitor for multiple myeloma originating from a licensing deal with Karyopharm. Stemline has an extensive clinical pipeline of small molecules and biologics in various stages of development for a host of solid and hematologic ...
These cell lines, or clones, are obtained from immunized animals by fusing B cells with myeloma cells. Meanwhile, monoclonal antibodies have monovalent affinity and can only recognize the same epitope of an antigen. ...
XPOVIO® is approved in mainland China for the following indication: In combination with dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma (R/R MM) who have received prior therapies and whose disease is refractory to at least one proteasome inhibitor, at least one immunomodulatory agent, and an anti-CD38 monoclonal antibody. ...
“We are encouraged by these results and believe STAR-LLD has the potential to provide a significant benefit to patients with multiple myeloma, lymphomas, and CLL.” Five groups of animals (n=10 per group) were implanted with RPMI 8226 cells. ...
Additionally, Sutro is collaborating with Bristol Myers Squibb (BMS) on CC-99712, a BCMA-targeting ADC in the clinic for patients with multiple myeloma; with Merck KGaA, Darmstadt, Germany, known as EMD Serono in the U.S. and Canada (EMD Serono), on M1231, a MUC1-EGFR bispecific ADC in clinical studies for patients with solid tumors, particularly non-small cell lung cancer ...
ATG-008 has been studied in clinical trials to treat a broad range of tumor types including multiple myeloma (MM), glioblastoma (GBM), hepatocellular carcinoma (HCC), non-small cell lung cancer (NSCLC), diffuse large B-cell lymphoma (DLBCL), etc. ...
Goldberg has served most recently as Vice President, Early Clinical Development, at Janssen supervising the clinical programs for multiple myeloma, cellular therapy, prostate cancer, as well as clinical pharmacology. ...
ByBayer AG
Additionally, Sutro is collaborating with Bristol Myers Squibb (BMS) on CC-99712, a BCMA-targeting ADC in the clinic for patients with multiple myeloma; with Merck KGaA, Darmstadt, Germany, known as EMD Serono in the U.S. and Canada (EMD Serono), on M1231, a MUC1-EGFR bispecific ADC in clinical studies for patients with solid tumors, particularly non-small cell lung cancer ...
Additionally, Sutro is collaborating with Bristol Myers Squibb (BMS) on CC-99712, a BCMA-targeting ADC in the clinic for patients with multiple myeloma; with Merck KGaA, Darmstadt, Germany, known as EMD Serono in the U.S. and Canada (EMD Serono), on M1231, a MUC1-EGFR bispecific ADC in clinical studies for patients with solid tumors, particularly non-small cell lung cancer ...
During her time at the Charité Universitätsmedizin Berlin in Germany, Blum, MD, PhD played a central role in developing a GMP-compliant clinical platform for the use of TCR based cellular therapy in refractory AML, high-risk multiple myeloma and metastatic melanoma. In the context of complex government-sponsored initiatives she was able to coordinate activities of ...
ByArdigen
To date, multiple XPOVIO® regimens have been added to the clinical guidelines of major oncology societies in the U.S., the EU, and APAC, including 5 regimens for the treatment of myeloma and 1 regimen for the treatment of lymphoma added to the guidelines of the National Cancer Care Network (NCCN); 4 regimens for the treatment of myeloma and 1 regimen for the ...
They have a wide range of indications, involving brain tumor, esophageal tumor, ovarian tumor, multiple myeloma, advanced solid tumor, pancreatic tumor, etc. Compared to ADCs, the synthesis and structural modifications of PDCs can be easily obtained, supporting rational drug design to improve bioavailability, affinity, and stability. ...
Additionally, Sutro is collaborating with Bristol Myers Squibb (BMS) on CC-99712, a BCMA-targeting ADC in the clinic for patients with multiple myeloma; with Merck KGaA, Darmstadt, Germany, known as EMD Serono in the U.S. and Canada (EMD Serono), on M1231, a MUC1-EGFR bispecific ADC in clinical studies for patients with solid tumors, particularly non-small cell lung cancer ...
Additionally, Sutro is collaborating with Bristol Myers Squibb (BMS) on CC-99712, a BCMA-targeting ADC in the clinic for patients with multiple myeloma; with Merck KGaA, Darmstadt, Germany, known as EMD Serono in the U.S. and Canada (EMD Serono) on M1231, a MUC1-EGFR bispecific ADC in clinical studies for patients with solid tumors, particularly non-small cell lung cancer (NSCLC) ...
Additionally, Sutro is collaborating with Bristol Myers Squibb (BMS) on CC-99712, a BCMA-targeting ADC in the clinic for patients with multiple myeloma; with Merck KGaA, Darmstadt, Germany, known as EMD Serono in the U.S. and Canada (EMD Serono), on M1231, a MUC1-EGFR bispecific ADC in clinical studies for patients with solid tumors, particularly non-small cell lung cancer ...
The delivery system and program have proven viability and we believe we are well situated to advance to Phase 1b/2 in multiple myeloma patients.” The Company previously announced that the upcoming Phase 1b/2 clinical study in multiple myeloma is on track to begin enrollment in Q4 2022 at three already identified sites in the European Union. ...